Dementia Researcher

The Dementia Researcher, ISTAART Relay Podcast is back for a fourth series. Five leading researchers discussing their research, their field, and the work of the Alzheimer’s Association ISTAART Professional Interest Area they represent. -- Part Two – Dr Maura Malpetti interviews Beth Eyre, representing the Vascular Cognitive Disorders PIA. -- Maura Malpetti is a Race Against Dementia Fellow at University of Cambridge. Maura focusses on multimodal imaging techniques (multi-tracer PET and MRI) integrated with fluid markers, post-mortem validation, and prognostic modelling approaches in frontotemporal lobar degeneration. Maura is representing the ISTAART Frontotemporal Dementia PIA. -- Beth Eyre is a PhD Student (although she recently submitted her thesis and will be defending very soon) at The University of Sheffield. Beth is investigating cognitive and neurovascular function in pre-clinical models of Alzheimer’s disease and in a mixed model of Alzheimer’s and atherosclerosis. Beth is representing the ISTAART Vascular Cognitive Disorders PIA. -- The Alzheimer’s Association International Society to Advance Alzheimer’s Research and Treatment (ISTAART) convenes the global Alzheimer’s and dementia science community. Members share knowledge, fuel collaboration and advance research to find more effective ways to detect, treat and prevent Alzheimer’s and other dementias. Professional Interest Areas (PIA) are an assembly of ISTAART members with common subspecialties or interests. -- There are currently 29 PIAs covering a wide range of interests and fields, from the PIA to Elevate Early Career Researchers to Biofluid Based Biomarkers and everything in between. To sign-up to ISTAART and a PIA visit: https://istaart.alz.org Note: ISTAART Membership is free for students worldwide, and for researchers of all levels based in Low- and Middle-Income Countries. -- To book your place at this year’s AAIC (In-person and online) visit: https://aaic.alz.org -- You can also enjoy this show as a video podcast on our YouTube channel at: https://youtu.be/sIPLKvDtQUk -- Find more information on our guests, and a full transcript of this podcast on our website at: https://www.dementiaresearcher.nihr.ac.uk/podcast -- The views and opinions expressed by guests in this podcast represent those of the guests and do not necessarily reflect those of NIHR Dementia Researchers, PIA membership, ISTAART or the Alzheimer's Association.

Adam Smith asked us to interupt our usual schedule to bring you some special news... The 2022 Dementia Research Charity Chatathon LIVE will take place on Friday 2nd December. Adam will host 12+ hours non-stop chat with over 60 researchers and special guests working accross all areas of discovery to beat Alzheimer's disease and all forms of dementia. Raising money for Alzheimer's Research UK, Alzheimer's Society, Race Against Dementia and The Lewy Body Society and providing insights into the latest research taking place across the UK and Worldwide. Find details on the event and liverstream speakers, schedule and how to make a donation at: http://www.chatathon.uk Be sure to also tell all your friends and colleagues. -- Note Dementia Researcher is not officially involved in this event, we're just delighted to support this great work, direct and questions or queries directly to [email protected]

In this podcast Dr Anna Volkmer, convenes a panel of world-renowned experts from University College London. They discuss the discovery of amyloid and its role in Alzheimer’s Disease and take an in-depth look into the latest developments surrounding Lecanemab and Donanemab, monoclonal antibodies (mAbs) as a treatment and Gene Silencing. This week’s guests are Professor Sir John Hardy, Geneticist and trailblazer in neurodegenerative disease research, Professor Nick Fox, Neurologist, and eminent figure in the fields of neuroimaging and clinical neuroscience, and Dr Cath Mummery, Neurologist and leading light in cognitive disorders and clinical trials. -- Listeners can expect: 1. 🧠 - Discussion on new dementia drugs Lecanemab and Donanemab. 2. 🔬 - Insights on the science behind these treatments, the story behind the discovery of amyloid and familial Alzheimer’s - Carol Jennings Story. 3. ❌🤔 - Clarification of misconceptions about dementia therapies. 4. 🩺💊 - Information on the impact of these drugs on patients and clinical practice. 5. 🌟🔜 - A look at the future of dementia research, including gene-silencing therapies. -- NIA statement on report of lecanemab reducing cognitive decline in Alzheimer’s clinical trial: https://www.nia.nih.gov/news/nia-statement-report-lecanemab-reducing-cognitive-decline-alzheimers-clinical-trial NIA statement on donanemab results: More Alzheimer’s research progress: https://www.nia.nih.gov/news/nia-statement-donanemab-results-more-alzheimers-research-progress Alzheimer's Society Information on Donanemab: https://www.alzheimers.org.uk/blog/what-is-donanemab-alzheimers-drug Alzheimer's Society Information on Lebanemab: https://www.alzheimers.org.uk/blog/lecanemab-new-drug-early-stage-alzheimers-disease Alzheimer's Association Info on Research & Risks https://bit.ly/3QxH3Ei -- Full biographies on all our guests and a transcript can be found on our website http://www.dementiaresearcher.nihr.ac.uk -- Like what you hear? Please review, like, and share our podcast - and don't forget to subscribe to ensure you never miss an episode – and if you prefer to watch rather than listen, you’ll find a video version of this podcast with full captions on our YouTube Channel. https://youtu.be/Kl8rzDSIwxM -- This podcast is brought to you by University College London / UCLH NIHR Biomedical Research Centre in association with Alzheimer’s Association, Alzheimer's Research UK, Alzheimer's Society and Race Against Dementia who we thank for their ongoing support.

Last week we were in Aberdeen for the Alzheimer’s Research UK Conference 2023 to hear the latest findings in dementia research. In the second of our two-part special we focus on sharing highlights from the main conference, which featured two days of brilliant scientific programming. Guest host Dr Zara Franklin from University of Aberdeen talks with Dr Natalie Connor-Robson from the UK Dementia Research Institute at Cardiff University, Dr Szu-Han Wang from The University of Edinburgh and Dr Steven Quinn from University of York. Full biographies on all our guests and a transcript can be found on our website: https://www.dementiaresearcher.nihr.ac.uk -- Like what you hear? Please review, like, and share our podcast - and don't forget to subscribe to ensure you never miss an episode – and if you prefer to watch rather than listen, you’ll find a video version of this podcast with full captions on our YouTube Channel: https://www.youtube.com/dementiaresearcher -- This podcast is brought to you by University College London / UCLH NIHR Biomedical Research Centre in association with Alzheimer’s Association, Alzheimer's Research UK, Alzheimer's Society and Race Against Dementia who we thank for their ongoing support.

Over the past decade, blood-based biomarkers for dementia have been increasingly studied as way to diagnose and track the progress of Alzheimer’s and other neurodegenerative diseases. In this podcast three leading blood-based biomarker pioneers come together to discuss the field, their research and motivations, current challenges and future directions of this field of research (they also reveal a little about themselves as people away from the lab too – find out which if them wants to drive refuse trucks...). In the host chair is Dr Nicholas Ashton, Associate Professor of Neurochemistry from University of Gothenburg and King’s College London. Nicks has more than a decade of experience in biofluid analysis and assay development for Alzheimer’s disease, which ranges from discovery mass spectrometry methods to ultra-sensitive immunoassays. Recently this has produced ultra-sensitive single molecular array (Simoa) assays for phosphorylated tau in blood, which are now widely used in research settings, therapeutics trials and being validated for clinical use. -- Nick’s guests are: Oskar Hansson, Professor of Neurology & Senior Consultant in Neurology at Lund University in Sweden. Oskar explores fluid and imaging biomarkers for neurodegenerative disorders. His inspiration came at medical school when diagnosing dementias. It became clear to him that we needed to be able to identify these diseases before widespread neurodegeneration and disabling symptoms have already developed. At these early disease stages, we are more likely to substantially slow down or even stop the disease progression by different types of interventions. Henrik Zetterberg, Professor of Neurochemistry, Senior Consultant in Clinical Chemistry, Head of Department at UK Dementia Research Institute at University College London and University of Gothenburg. With a background in molecular biology and medicine, Henrik has have spent the last 15 years developing biomarkers for Alzheimer's disease and other brain disorders - becoming a world expert in the process. He has published more than 1100 scientific articles and has received numerous awards. -- If you’re listening to this podcast, you probably already know that Biomarkers are proteins, molecules, or other measurable substances that can provide valuable insight into diagnosing and measuring the progression of a medical condition or disease. For a many years researchers have been exploring the potential of what can discover from blood, to help diagnose Alzheimer’s and other Neurodegenerative diseases. -- You can find out more about our panellists, and their work on our website. There you will also find a full transcript: https://www.dementiaresearcher.nihr.ac.uk -- Like what you hear? Please review, like, and share our podcast - and don't forget to subscribe to ensure you never miss an episode. -- This podcast is brought to you by University College London / UCLH NIHR Biomedical Research Centre in association with Alzheimer’s Association, Alzheimer's Research UK, Alzheimer's Society and Race Against Dementia who we thank for their ongoing support.